Note 1 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2012

		Three Months Ended September 30,						Nine Months Ended September 30,
Licensee	Product Name	2012			2011			2012			2011
Genentech, Inc. (Genentech)	Avastin®		30	%		28	%		31	%		30	%
	Herceptin®		36	%		38	%		35	%		34	%
	Lucentis®		15	%		15	%		18	%		16	%
Elan Corporation, Plc (Elan)	Tysabri®		14	%		14	%		12	%		11	%